Iressa as a First-Line Treatment in Chemonaive Patients With Inoperable Non-Small Cell Lung Cancer

Phase 2 Completed 108 enrolled National Taiwan University Hospital

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the overall response rate to Iressa as a first-line treatment in chemonaive patients with inoperable Non-Small Cell Lung Cancer (NSCLC)

Timeline

Start: 2005-03
Primary completion: —
Completion: 2007-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gefitinib	Small molecule	—	Oral

Iressa as a First-Line Treatment in Chemonaive Patients With Inoperable Non-Small Cell Lung Cancer

Summary

Timeline

Drugs

Indications